In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Deepak L. Bhatt, MD, MPH
Director, Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bhatt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Angiowave, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., CellProthera, Cereno Scientific, GlaxoSmithKline, Hims & Hers Health, Inc., Janssen Biotech, Inc., Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio Pharmaceuticals, Inc., PLx Pharma, SFJ Pharmaceuticals, Stasys Medical Corporation, Youngene Therapeutics
Contracted Research: 89Bio, Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam Pharmaceuticals, Inc, Amarin Corporation plc, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bayer, Beren, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc., Boston Scientific, Bristol Myers Squibb Company, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor Pharma, Inc., Cleerly, CSI, CSL Behring, Eisai Co., Ltd., Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Biotech, Inc., Javelin, Lexicon Pharmaceuticals, Inc., Lilly, Medtronic, Inc., Merck, Moderna, Inc., MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka Pharmaceutical Co., Ltd., Owkin, Pfizer, Inc., PhaseBio Pharmaceuticals, Inc., Philips, PLx Pharma, Recardio, Regeneron Pharmaceuticals, Inc., Roche, Sanofi, SpectraWAVE, Stasys Medical Corporation, Synaptics, The Medicines Company, Vascular Solutions, Youngene Therapeutics
Patent Beneficiary: Lexicon Pharmaceuticals, Sotagliflozin
Stock Options: Angiowave, Bristol Myers Squibb Company
Manesh R. Patel, MD
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke Clinical Research Institute, Duke University
Durham, NC
Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, Janssen, Novartis
Contracted Research: AstraZeneca, Bayer, Janssen, Mytomy, Procyrion
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Mario P. Trucillo, PhD, MS, has nothing to disclose.